Abstract
In this review we examine, in the context of the AT(N) framework, the available evidence as well as the potential alternatives on how to establish tau-positivity (T+) for multiple tau imaging tracers in order to come to a consensus for “normal” and “abnormal” tau imaging values that can be universally implemented in clinical research and therapeutic trials.
- Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
In this issue
Jump to section
Related Articles
Cited By...
- Differential effects of aging, Alzheimers pathology, and APOE4 on longitudinal functional connectivity and episodic memory in older adults
- Improved Correlation of 18F-Flortaucipir PET SUVRs and Clinical Stages in the Alzheimer Disease Continuum with the MUBADA/PERSI-Based Analysis
- Plasma p-tau217 predicts cognitive impairments up to ten years before onset in normal older adults
- CenTauR: Towards a Universal Scale and Masks for Standardizing Tau Imaging Studies
- Tau PET Imaging in Neurodegenerative Disorders
- AT(N) predicts near-term development of Alzheimers disease symptoms in unimpaired older adults
- Tau Imaging with 18F-MK6240 across the Alzheimers Disease spectrum